SUBSCRIBE

Breaking News on Global Pharmaceutical Technology & Manufacturing

Headlines > Regulatory & Safety

Read more breaking news

 

 

EMA Offers Inside Look at Clinical Trial Inspections

By Zachary Brennan , 31-Jan-2013
Last updated on 31-Jan-2013 at 13:41 GMT

EMA Offers Inside Look at Clinical Trial Inspections

Clinical trial inspectors are being called on by the European Medicines Agency (EMA) to focus their efforts more on findings that are likely to impact the benefit-risk evaluation of a drug.

Deficiencies in a sponsor, CRO or other organisation delegated responsibility by the sponsor but unrelated to the clinical trial site are almost alyways systemic, the EMA says in its points to consider document to help inspectors draft their reports.

But deficiencies found at trial sites are more difficult to address. The EMA cautiously notes that identifying good clinical practice (GCP) noncompliance at one site could be an isolated finding, especially if a trial involves multiple sites. But if the same finding is identified “at two different investigational sites (preferably in different countries/regions), it greatly increases the probability that the finding reflects a general problem with the study.”

Analyses of sponsors’ clinical databases may be a way to “shed more light on the issue of how to generalize inspection findings,” the EMA notes, particularly if a problem leaves an identifiable footprint on the database. For example, investigators applying identical scores of a psychometric test to patients throughout a study could be identified through specific searches in the clinical database.

The EMA focuses on findings that should be of particular importance for inspectors, noting the top eight GCP inspection findings most likely to impact a risk-benefit evaluation are:

  • Deficiencies in the blinding of a medication, particularly if it leads to bias related to patient reported outcomes, psychometric tests and other subjective endpoints;
  • Problems with randomization that raise questions about the comparability of the treatment groups and the relationship between treatment and effect;
  • Violation of diagnostic inclusion- and exclusion criteria
  • Violation of procedures related to the assessment of the primary efficacy endpoint;
  • Inadequate reporting of adverse events and other safety endpoints;
  • Missing source documentation;
  • Faults in data management, statistical programming and analyses, though difficult to detect, especially at the level of sponsor or CRO, have the potential to lead to completely false study conclusions; and
  • Fraud and other scientific misconduct.

But even inspection findings outside of those most likely to impact the benefit-risk evaluation can become significant if several of them seem to indicate overall poor data quality, according to the EMA. One such example is a failure to document pre-specification of analyses prior to breaking a study blind so as to avoid analyses tailored to the trial’s findings.

In addition, major ethical flaws, even ones not directly influencing a benefit-risk assessment, “should have an impact on the final conclusions about approvability of an application,” the EMA notes.

Related products

Key Industry Events

 

Access all events listing

Our events, Events from partners...

Products

Solid Lipid Excipients: Born to be Extruded !
Gattefossé Pharma
USP<233> Elemental Impurities Sample Prep Strategy
SGS Life Science Services
Online Cell Density Monitoring
Hamilton Bonaduz AG
Residual moisture in lyophilized pharmaceuticals
Metrohm – customized analysis for the pharmaceutical industry
Need help to bring insoluble APIs to the market?
Dow Pharma & Food Solutions